P595 Feasibility and performance of a fully automated endoscopic disease severity grading tool for ulcerative colitis using unaltered multisite videos
ECCO'20 Vienna
2020
P596 Risk of colorectal cancer and other malignancies in association with the use of thiopurines, tumour necrosis factor antagonists or mesalazine
ECCO'20 Vienna
2020
P597 Pooled safety analyses from Phase 3 studies of filgotinib in patients with rheumatoid arthritis
ECCO'20 Vienna
2020
P599 Trimester exposure and pregnancy outcomes in women exposed to golimumab: Results from the company pharmacovigilance database
ECCO'20 Vienna
2020
P603 Persistence of vedolizumab maintenance therapy: Findings from a Belgian registry
ECCO'20 Vienna
2020
P604 Can we reduce intravenous monoclonal antibody observation times without compromising patient safety? A single centre retrospective observational study
ECCO'20 Vienna
2020
P605 Eight-year efficacy and safety of azathioprine treatment in the maintenance of steroid-free remission in inflammatory bowel disease patients
ECCO'20 Vienna
2020
P606 Exclusive enteral nutrition with a polymeric diet is efficacious in inducing remission in adults with active Crohn’s disease
ECCO'20 Vienna
2020
P607 Cost-effectiveness of vedolizumab IV vs. adalimumab SC for moderately to severely active ulcerative colitis
ECCO'20 Vienna
2020
P609 An IBD dermatology multidisciplinary clinic: A single tertiary centre experience
ECCO'20 Vienna
2020
P610 Optimising biological therapy in inflammatory bowel disease patients: the role of a virtual biological clinic
ECCO'20 Vienna
2020
P611 Provision of care for pregnant women with IBD in the UK - the current landscape
ECCO'20 Vienna
2020
P612 Dietary practices and beliefs of British South Asians with inflammatory bowel disease: A prospective UK study
ECCO'20 Vienna
2020